Once-weekly subcutaneous semaglutide and lifestyle intervention is associated with sustained and clinically relevant mean weight loss of about 14.9% in adults with obesity.
The facts about obesity.
According to the Centers for Disease Control and Prevention (2018), an individual with a body mass index (BMI) at the 90th percentile is at risk of suffering from obesity or being overweight.
Additionally, once-weekly subcutaneous semaglutide and lifestyle intervention in adults with obesity is associated with sustained and clinically relevant mean weight loss of about 14.9%.
Read more on obesity here: https://brainly.com/question/5412536
#SPJ1
